INTELLIA THERAPEUTICS, INC. Financing Cash Flow
INTELLIA THERAPEUTICS, INC. (NTLA) reported Financing Cash Flow of $229.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $196.12M, a 1238.49% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $33.57M.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.98M, a 14.67% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $114.86M, a 39.74% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $131.49M, a 29.21% decline from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $185.75M, a 42.53% increase from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $130.32M, a 77.64% decline from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $582.96M, a 20.87% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $196.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $229.69M 10-Q · filed 2026-08-06 | $231.66M derived: sum of 3 quarters · filed 2026-08-06 | $346.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $33.57M 10-Q · filed 2026-05-11 | $35.55M derived: sum of 2 quarters · filed 2026-05-11 | $150.40M derived: sum of 3 quarters · filed 2026-05-11 | $165.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $116.83M derived: sum of 2 quarters · filed 2026-02-26 | $131.49M derived: sum of 3 quarters · filed 2026-08-06 | $131.49M 10-K · filed 2026-02-26 |
| 2025-09-30 | $114.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $129.51M derived: sum of 2 quarters · filed 2026-08-06 | $129.51M 10-Q · filed 2025-11-06 | $131.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $14.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.65M 10-Q · filed 2026-08-06 | $16.97M derived: sum of 3 quarters · filed 2026-08-06 | $99.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | $2.32M derived: sum of 2 quarters · filed 2026-05-11 | $84.51M derived: sum of 3 quarters · filed 2026-05-11 | $125.75M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $84.51M derived: sum of 2 quarters · filed 2026-02-26 | $125.75M derived: sum of 3 quarters · filed 2026-02-26 | $185.75M 10-K · filed 2026-02-26 |
| 2024-09-30 | $82.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $123.44M derived: sum of 2 quarters · filed 2025-11-06 | $183.43M 10-Q · filed 2025-11-06 | $289.91M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $41.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $101.24M 10-Q · filed 2025-08-07 | $207.72M derived: sum of 3 quarters · filed 2026-02-26 | $226.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $59.99M 10-Q · filed 2025-05-08 | $166.48M derived: sum of 2 quarters · filed 2026-02-26 | $185.58M derived: sum of 3 quarters · filed 2026-02-26 | $188.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $106.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $125.59M derived: sum of 2 quarters · filed 2026-02-26 | $128.10M derived: sum of 3 quarters · filed 2026-02-26 | $130.32M 10-K · filed 2026-02-26 |
| 2023-09-30 | $19.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $21.62M derived: sum of 2 quarters · filed 2024-11-07 | $23.84M 10-Q · filed 2024-11-07 | $529.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.74M 10-Q · filed 2024-08-08 | $510.50M derived: sum of 3 quarters · filed 2025-02-27 | $534.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.22M 10-Q · filed 2024-05-09 | $507.98M derived: sum of 2 quarters · filed 2025-02-27 | $531.96M derived: sum of 3 quarters · filed 2025-02-27 | $537.86M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $505.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $529.74M derived: sum of 2 quarters · filed 2025-02-27 | $535.63M derived: sum of 3 quarters · filed 2025-02-27 | $582.96M 10-K · filed 2025-02-27 |
| 2022-09-30 | $23.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $29.87M derived: sum of 2 quarters · filed 2023-11-09 | $77.19M 10-Q · filed 2023-11-09 | $79.47M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $5.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $53.22M 10-Q · filed 2023-08-03 | $55.49M derived: sum of 3 quarters · filed 2024-02-22 | $724.17M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $47.32M 10-Q · filed 2023-05-04 | $49.60M derived: sum of 2 quarters · filed 2024-02-22 | $718.28M derived: sum of 3 quarters · filed 2024-02-22 | $725.41M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $670.96M derived: sum of 2 quarters · filed 2024-02-22 | $678.09M derived: sum of 3 quarters · filed 2024-02-22 | $736.69M 10-K · filed 2024-02-22 |
| 2021-09-30 | $668.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $675.81M derived: sum of 2 quarters · filed 2022-11-03 | $734.41M 10-Q · filed 2022-11-03 | $968.50M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $7.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $65.73M 10-Q · filed 2022-08-04 | $299.82M derived: sum of 3 quarters · filed 2023-02-23 | $300.42M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $58.59M 10-Q · filed 2022-05-05 | $292.69M derived: sum of 2 quarters · filed 2023-02-23 | $293.29M derived: sum of 3 quarters · filed 2023-02-23 | $425.51M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $234.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $234.69M derived: sum of 2 quarters · filed 2023-02-23 | $366.92M derived: sum of 3 quarters · filed 2023-02-23 | $371.78M 10-K · filed 2023-02-23 |
| 2020-09-30 | $597.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $132.82M derived: sum of 2 quarters · filed 2021-11-04 | $137.69M 10-Q · filed 2021-11-04 | $157.25M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $132.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $137.09M 10-Q · filed 2021-08-05 | $156.65M derived: sum of 3 quarters · filed 2022-02-24 | $203.05M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $4.86M 10-Q · filed 2021-05-06 | $24.43M derived: sum of 2 quarters · filed 2022-02-24 | $70.83M derived: sum of 3 quarters · filed 2022-02-24 | $77.30M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $19.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $65.96M derived: sum of 2 quarters · filed 2022-02-24 | $72.44M derived: sum of 3 quarters · filed 2022-02-24 | $76.43M 10-K · filed 2022-02-24 |
| 2019-09-30 | $46.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $52.87M derived: sum of 2 quarters · filed 2020-11-05 | $56.87M 10-Q · filed 2020-11-05 | $87.03M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $6.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $10.47M 10-Q · filed 2020-08-06 | $40.63M derived: sum of 3 quarters · filed 2021-02-26 | $42.81M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $4.00M 10-Q · filed 2020-05-07 | $34.16M derived: sum of 2 quarters · filed 2021-02-26 | $36.34M derived: sum of 3 quarters · filed 2021-02-26 | $37.50M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $30.16M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $32.34M derived: sum of 2 quarters · filed 2021-02-26 | $33.50M derived: sum of 3 quarters · filed 2021-02-26 | $40.22M 10-K · filed 2021-02-26 |
| 2018-09-30 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $3.33M derived: sum of 2 quarters · filed 2019-10-31 | $10.05M 10-Q · filed 2019-10-31 | $152.17M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $7.88M 10-Q · filed 2019-08-01 | $149.99M derived: sum of 3 quarters · filed 2020-02-27 | $150.36M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $6.72M 10-Q · filed 2019-05-02 | $148.84M derived: sum of 2 quarters · filed 2020-02-27 | $149.21M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | $142.12M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $142.49M derived: sum of 2 quarters · filed 2020-02-27 | $142.98M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $371.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $864.00K 10-Q · filed 2018-10-31 | ||
| 2017-06-30 | $493.00K 10-Q · filed 2018-08-01 | |||
| 2016-12-31 | $167.30M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |